stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Outset Medical, Inc.

United States · NASDAQ: OM · Market cap: $66.8M · P/E: loss · P/S: 0.6

Outset Medical sells a compact, all-in-one machine that hospitals and clinics use to give patients dialysis treatment.

Outset Medical makes a machine called Tablo, a compact dialysis system that does the work of cleaning a patient's blood when their kidneys can't. Dialysis is a life-supporting treatment for people whose kidneys have failed, and it has traditionally required bulky equipment, special plumbing, and a dedicated room. Tablo is designed to be smaller and simpler, so a hospital can run it at a patient's bedside and a clinic or even a home-care setting can use it without a major construction project.

Outset Medical, Inc. (OM) Tablo hemodialysis system: line art illustration of Tablo dialysis machine on a wheeled cart
Tablo dialysis system
Tablo is a dialysis machine designed to make treatment simpler to run.

The company sells Tablo systems and the related supplies and services that go with them to hospitals, dialysis clinics, and other healthcare providers. It makes money both from placing the machines and from the ongoing consumables and service contracts that each treatment requires. That razor-and-blades model matters: a machine that sits in a hospital and gets used repeatedly generates a steady stream of recurring revenue, not just a one-time sale. The big idea behind Outset is that dialysis has been stuck in specialized centers for decades, forcing patients to travel several times a week for hours-long sessions. Tablo's pitch is flexibility — treat patients where they already are, whether that's a hospital bed, a nursing facility, or eventually the home. That bet has been expensive to build, and the company has burned through cash while scaling up manufacturing and its sales force.


Outset is a small, unprofitable company taking on much larger, entrenched players in kidney care, and its stock has been volatile as investors weigh how fast Tablo adoption can grow against its cash burn. It's a genuine medical-technology bet: a simpler machine that could reshape where dialysis happens, if enough providers buy in before the money runs out.

Saved answer · last researched 16 Nov 2026